Literature DB >> 11782057

On the inappropriateness of an EM algorithm based procedure for blinded sample size re-estimation.

Tim Friede1, Meinhard Kieser.   

Abstract

When planning a clinical trial the sample size calculation is commonly based on an a priori estimate of the variance of the outcome variable. Misspecification of the variance can have substantial impact on the power of the trial. It is therefore attractive to update the planning assumptions during the ongoing trial using an internal estimate of the variance. For this purpose, an EM algorithm based procedure for blinded variance estimation was proposed for normally distributed data. Various simulation studies suggest a number of appealing properties of this procedure. In contrast, we show that (i) the estimates provided by this procedure depend on the initialization, (ii) the stopping rule used is inadequate to guarantee that the algorithm converges against the maximum likelihood estimator, and (iii) the procedure corresponds to the special case of simple randomization which, however, in clinical trials is rarely applied. Further, we show that maximum likelihood estimation leads to no reasonable results for blinded sample size re-estimation due to bias and high variability. The problem is illustrated by a clinical trial in asthma. Copyright 2002 John Wiley & Sons, Ltd.

Mesh:

Substances:

Year:  2002        PMID: 11782057     DOI: 10.1002/sim.977

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  4 in total

1.  EM Estimation for Finite Mixture Models with Known Mixture Component Size.

Authors:  Chen Teel; Taeyoung Park; Allan R Sampson
Journal:  Commun Stat Simul Comput       Date:  2015-07       Impact factor: 1.118

2.  Maximum type I error rate inflation from sample size reassessment when investigators are blind to treatment labels.

Authors:  Magdalena Żebrowska; Martin Posch; Dominic Magirr
Journal:  Stat Med       Date:  2015-12-23       Impact factor: 2.373

3.  Blinded and unblinded sample size reestimation in crossover trials balanced for period.

Authors:  Michael J Grayling; Adrian P Mander; James M S Wason
Journal:  Biom J       Date:  2018-08-03       Impact factor: 2.207

4.  Blinded continuous monitoring in clinical trials with recurrent event endpoints.

Authors:  Tim Friede; Dieter A Häring; Heinz Schmidli
Journal:  Pharm Stat       Date:  2018-10-21       Impact factor: 1.894

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.